Pain Management and Rehabilitation INC.

Pain Management and Rehabilitation INC. was paid $622K by Medicaid between Jan 2018 and Nov 2023, across 18 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 25% of everything it billed.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	8,328	$273K
2019	5,732	$165K
2020	3,073	$48K
2021	3,865	$64K
2022	4,258	$68K
2023	152	$3K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	25%	10,346	7,380	$154K
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	20%	6,063	4,212	$125K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	16%	654	626	$99K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	13%	438	410	$78K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	12%	1,650	1,518	$77K
27096		5.8%	266	191	$36K
20611		4.5%	1,020	576	$28K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	1.7%	84	80	$10K
J0702	Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg	<1%	1,607	985	$5K
94761		<1%	474	349	$4K
J1030	Injection, methylprednisolone acetate, 40 mg	<1%	710	469	$2K
99204	Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity	<1%	21	13	$1K

6 more codes

S0020	Injection, bupivicaine hydrochloride, 30 ml	<1%	891	$950.32
76942		<1%	14	$706.04
77003		<1%	380	$173.68
82948		<1%	77	$127.34
J1100	Injection, dexamethasone sodium phosphate, 1 mg	<1%	42	$1.74
A4550	Surgical trays	0%	671	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialREHMAN, KHALIQUE (PHYSICIAN)